Skip to content

POP-UP: a Single-arm, Two-cohort Study: Trimodal Prehab for Upper GI and Pancreatic Cancer

Trimodal Peri Operative Prehabilitation for Upper Oesogastric and Pancreatic Cancer: A Multicenter, Two-cohort, Open-label, Single-arm POP-UP GERCOR Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06275737
Acronym
POP-UP
Enrollment
72
Registered
2024-02-23
Start date
2024-06-24
Completion date
2028-06-30
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Ductal Adenocarcinoma, Esophageal Cancer

Brief summary

This is a multicenter, two-cohort, open-label, single-arm feasibility study. The primary objective is to assess the feasibility of the 8-week trimodal prehabilitation program alongside perioperative triplet chemotherapy in eligible patients with localized pancreatic ductal adenocarcinoma (PDAC) or oesogastric cancer (OGC) .

Detailed description

The POP-UP study aims to evaluate the feasibility and preliminary efficacy of an 8-week trimodal pre/posthabilitation program (consisting of personalized Adapted Physical Activity \[APA\], nutritional assessment, and psychological support) with remote monitoring of the APA sessions and nurse coordination in patients with localized (resectable or borderline resectable) PDAC who are treated with neoadjuvant or induction treatment (FOLFIRINOX: 5-fluorouracil/folinic acid, oxaliplatin, irinotecan) prior to surgery and with resectable OGC treated with perioperative chemotherapy (FLOT: 5-fluorouracil/folinic acid, oxaliplatin, docetaxel). The prehabilitation program will be conducted during neoadjuvant chemotherapy and the 3-5 weeks prior to surgery for a total of 8 weeks before surgery. There will be a total of three prehabilitation hospital days during the prehabilitation program. The preoperative prehabilitation will include: * Once per month, a prehabilitation hospital-day with functional capacities assessment with validated tests made by a physiotherapist or an APA professional (according of center resources/functioning), medical and nurse assessment evaluating performance status, chemotherapy toxicity and tolerance, and nutritional assessment (according to the functioning of each center it will be made by these professionals -with university training on nutrition- or a dietician). A therapeutic training session on the adherence to the prehabilitation program will be done by the nurse (trained in therapeutic education). * Weekly, an APA professional trainer will follow via using app (Activiti®) the APA home-based program. It will be based on the functional capacities assessment made during the prehabilitation hospital day. The exercise training program will consist of twice per week autonomy sessions, supervised and adapted by the APA professional, and once per week a guided session with the APA professional. The patient will have a total of 3 physical activity sessions per week. * Once per week, the nurse practitioner (or case manager, according to center functioning) will evaluate the patient via a videoconference to assess the chemotherapy toxicity and tolerance and patient's weight modifications. The posthabilitation program will start for a total of 8 weeks, one week after surgery discharge. The structure is the same as the prehabilitation program except for the follow of chemotherapy toxicity and tolerance that will be replaced by the follow of the surgical complications/consequences. There will be a total of three posthabilitation days at hospital during the posthabilitation program.

Interventions

Cohort 1 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 5 - cycle 6 or cycle 6 - cycle 8) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle) Cohort 2 - Prehabilitation program will be implemented during the last cycles of neoadjuvant chemotherapy (cycle 2 - cycle 4) and the weeks preceding surgery (planned 3-4 weeks after the last chemotherapy cycle)

Sponsors

GERCOR - Multidisciplinary Oncology Cooperative Group
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Two-cohort, open-label, single-arm feasibility study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed and dated patient informed consent form (ICF) and willingness to comply with all study procedures and availability for the study duration, * Histologically or cytologically localized PDAC or OGC validated by the multidisciplinary team, * Indication to a preoperative treatment withtriplet chemotherapy for ≥ 4 cycles (8 weeks), Note: Patient treated for PDAC, first cycle without oxaliplatin is authorized. * Age \> 18 years; If aged ≥ 75 years: G8 score must be ≥ 14 and if \< 14 validation of oncogeriatric specialist, * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1 at inclusion visit (first prehabilitation hospital-day), * No prior treatment for PDAC or OGC before screening visit, * At least one measurable or evaluable lesion as assessed by Computerized Tomography scan or Magnetic resonance imaging according to RECIST 1.1 and feasibility of repeated radiological assessments on baseline imaging before starting chemotherapy, * Adequate hematologic and end-organ function allowing the triple combination chemotherapy protocol, * Registration in a national health care system (PUMa - Protection Universelle Maladie included).

Exclusion criteria

* Evidence of metastatic disease at imaging (validated in multidisciplinary team evaluation), * Histology of other than adenocarcinoma, * Any medical (including cardiovascular, respiratory, psychiatric, musculoskeletal, or neurological) condition contra-indicating exercise practice, * Patients with medical contraindication to surgery due to general condition or comorbidities * Pregnancy or breast-feeding, * Patient under a legal protection regime (guardianship, curatorship, judicial safeguard) or administrative decision or incapable of giving his/her consent,

Design outcomes

Primary

MeasureTime frameDescription
Rate of patients with successful completion of an 8-week trimodal prehabilitation program8 weeksThe success of prehabilitation is defined by the achievement of the following three criteria: 1. Completion of at least 75% of the planned APA sessions: 6 of 8 sessions with an APA professional and 12 of 16 sessions in autonomy with remote APA supervision and 2. Completion of at least 75% of the nutritional evaluations: 6 of 8 planned evaluations and 3. Psychological or psychiatric visit before the surgery in function of practice center /resources if a psychological need is shown by Hospital Anxiety and Depression Scale

Secondary

MeasureTime frameDescription
Rate of patients who start and complete post-habilitation Adapted Physical Activity (APA) sessions8 weeksRate of patients who start and complete post-habilitation APA sessions; reasons for drop-out.
Success rate (as defined above) for Adapted Physical Activity (APA), nutritional, and psychological interventions measured separately.8 weeksThe success of APA, nutritional, and psychological interventions analyzed separately
Nutritional status assessment8 weeksNutritional status assessment by: Body mass index (BMI) - BMI will be calculated by dividing mass in kilograms (kg) by height in meters squared (m2). Food intake will be measured by visual analog scale SEFI \[Score d'Evaluation Facile des Ingesta=Ingesta Easy Evaluation Score\]). The SEFI is a score rated from 0 (nothing is consumed) to 10 (everything is consumed) in whole numbers. A SEFI \< 7/10 corresponds to decreased food intake and is associated with risk of malnutrition. A SEFI ≥ 7 corresponds to satisfactory food intake.
Physical/functional test assessment8 weeksFunctional tests: 6-minute waking test, handgrip test, one minute sit-to-stand (STS), assessment of Borg scale post physical exercise will be measured. A 6-minutes walking test (distance measured in meters) will be performed. Dyspnea will be measured by the Borg scale Borg scale (ratings of the effort to breathe; a scale from 0 to 10, where 0 represents no dyspnea and 10 represents maximal dyspnea). Scores are obtained at the end of the walking test and reflect the maximum degree of dyspnea at any time during the walk test. Handgrip test - hand grip strength will be measured using dynamometer in sitting position and will be expressed in kilograms (kg). One-minute sit-and-stand test - Patients will perform stand-and-sit transitions on the chair as many times as possible within one minute. Number of of repetitions will be measured.
Number of patients with reduced chemotherapy tolerance8 weeksChemotherapy tolerance: toxicities (Common Terminology Criteria for Adverse Events \[CTCAE\] v5.0) of grade ≥ 3, toxicities requiring hospitalization, treatment delays or dose reduction due to toxicities
Number of patients with chemotherapy dose modification8 weeksModification of the chemotherapy related dose-intensity relation on the completion or not of the prehabilitation program
Rate of patients who complete the strategy8 weeksRate of patients who undergo surgery and the total number of planned perioperative chemotherapy cycles, and number of cycles received / number of cycles planned
Health-related quality of life (HRQoL) assessmentUp to 3 yearsHRQoL assessed using the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) questionnaire for all patients.
Rate of patients with exocrine pancreatic insufficiency and the dose of pancreatic enzyme consumption8 weeksPreoperative and post-operative fecal elastase and pancreatic enzymes prescription and reported consumption
Rate of surgical complicationsAt 30 days after surgeryRate of surgical complications requiring reintervention or rehospitalisation (grade ≥ 3 in Clavien-Dindo classification) within 90 days after surgery, length of hospital stay
Overall survival (OS) assessmentFrom inclusion up to 12 months after surgeryOS defined as time between the date of inclusion and 12 months after surgery
Disease-free survival (DFS) assessmentFrom inclusion up to 12 months after surgeryDFS defined as the time between the date inclusion and the date corresponding at 12 months after surgery
Adherence to Adapted Physical Activity (APA) program assessment8 weeksAdherence to the APA program: by patient reported outcomes collected via Activiti® app and the APA professional assessment
Physical activity behavior changes assessment8 weeksSimplified International Physical Activity Questionnaire (IPAQ-S) will be administrated to assess physical activity and sedentary behavior changes. It is a 7-item questionnaire in which duration (hours and minutes per day), frequency (times per week), and intensity (walking, moderate and vigorous) of the previous 7 days will be collected. Sedentary time (self-reported time spent sitting) in the same time period will be recorded (hours/min/day).
Nurse coordination8 weeksNurses will evaluate chemotherapy tolerance with the CTCAE V5.0 (Grade ≥ 3) and weight lose once per week with Activiti® application.
Number of patients with Granulocyte-colony stimulating factor (G-CSF) prescription and grade ≥ 2 neutropenia8 weeksrate of patients' with GCSF prescription and grade ≥ 2 neutropenia

Countries

France

Contacts

Primary ContactMarie-Line GARCIA LARNICOL, MD
marie-line.garcia-larnicol@gercor.com.fr+33 (01) 40 29 85 04
Backup ContactEva Ester MOLINA BELTRAN
evaester.molinabeltran@curie.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026